


Attorney's Docket No. 44276/209251 (5854-2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#17  
*Amdt. C*  
1/22/03  
PATENT

In re: Kappes *et al.*

Confirmation No.: 7175

Appl. No.: 09/719,340

Group Art Unit: 1648

Filed: April 13, 2001

Examiner: S. Foley

For: CELL-BASED METHOD AND ASSAY FOR MEASURING THE INFECTIVITY  
AND DRUG SENSITIVITY OF IMMUNODEFICIENCY VIRUS

January 13, 2003

Commissioner for Patents  
Washington, DC 20231

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900

AMENDMENT

Sir:

In response to the Office Action mailed August 12, 2002, Applicants respectfully request reexamination and reconsideration of the above-identified application in view of the following amendments and remarks.

Please amend the above-referenced application as follows.

In The Claims:

Please amend claims 39, 43, and 48 as follows:

C1 39. (Amended) The immortalized cell of claim 37, wherein said marker gene encodes luciferase,  $\beta$ -galactosidase, green fluorescent protein, or a polypeptide that confers antibiotic resistance.

43. (Amended) A method for detecting a HIV virus comprising:

C2 cont'd. a) providing an immortalized cell characterized by expressing CCR5, CXCR4, and CD4 receptors and having stably incorporated a marker gene operably linked to a promoter, wherein expression of the marker gene occurs upon HIV infection of the immortalized cell;